By Fineline Cube 
China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the first commercial shipment of its self-developed Class 1 innovative drug Aiweida (trastuzumab rezetecan), marking the official market launch of the HER2-targeted antibody-drug conjugate (ADC).
Drug Approval and Indication
Trastuzumab rezetecan, developed independently by Hengrui, received approval in China last month. It is indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) activating mutations who have previously received at least one systemic therapy.
Clinical Trial Results
The approval was primarily based on the HORIZON-Lung study, which demonstrated an objective response rate (ORR) of 74.5% and a median progression-free survival (mPFS) of 11.5 months, with a 12-month PFS rate of 48.6% in previously treated HER2-mutated advanced or metastatic NSCLC patients.-Fineline Info & Tech